Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
J Virol. 2012 Mar;86(6):3393-7. doi: 10.1128/JVI.06745-11. Epub 2012 Jan 18.
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are being considered for passive prevention of infection. We analyzed the interaction of MAbs to two independent epitopes on the viral envelope glycoprotein. Potently neutralizing MAbs to the CD4 binding site and V1V2 region displayed no in vitro cross-competition and displayed additive, though not synergistic, neutralization activity. Predicted neutralization coverage of a combination of two MAbs reached 97% on a 208-isolate panel.
HIV-1 中和单克隆抗体 (MAbs) 定义了疫苗开发的关键目标，并且正在被考虑用于被动预防感染。我们分析了两种独立的病毒包膜糖蛋白表位上的 MAb 相互作用。对 CD4 结合位点和 V1V2 区域具有强大中和作用的 MAb 之间没有体外交叉竞争，表现出相加而非协同的中和活性。两种 MAb 组合的预测中和覆盖率在一个包含 208 个分离株的面板上达到 97%。
